Search results for "EPA"

showing 10 items of 8995 documents

Chylous ascites after lymphadenectomy for gynecological malignancies

2016

Background and Objectives Chylous ascites, an accumulation of milky-white lymph fluid in the peritoneal cavity, is a rare complication following retroperitoneal lymphadenectomy. This study evaluated the appearance and management of chylous ascites following lymphadenectomy for gynecological malignancies. Methods A total of 931 patients who underwent lymphadenectomy for gynecological malignancies at Erlangen University Hospital between 2002 and 2013 were reviewed retrospectively. Results Chylous ascites occurred postoperatively in 28 of the 931 patients (3.0%). All patients with chylous ascites had undergone combined systematic para-aortic and pelvic lymphadenectomy (SAPL). Patients with chy…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentRetrospective cohort studyGeneral Medicinemedicine.diseaseSurgery03 medical and health sciencesPeritoneal cavity0302 clinical medicinemedicine.anatomical_structureOncology030220 oncology & carcinogenesisChylous ascitesCarcinomamedicine030211 gastroenterology & hepatologySurgeryLymphadenectomyLymphComplicationbusinessLaparoscopyJournal of Surgical Oncology
researchProduct

Minimalheparinisierung bei Dialysepatienten mit erhöhter Blutungsgefährdung

2008

Abstract In 78 patients (47 men, 31 women; mean age 53 [22-78] years) 174 dialyses were undertaken within one week of a bleeding episode or a diagnostic or therapeutic procedure which may cause bleeding. Minimal anticoagulation with low molecular weight heparin (LMWH) was the aim, using a biocompatible dialyser. During the dialysis coagulation was controlled by global tests (Quick value/international normalized ratio [INR], partial thromboplastin time, thrombin time, antifactor Xa activity), by molecular markers of clotting activity (thrombin-antithrombin III complex [TAT], D-dimers), as well as measurement of elastase (elastase-alpha 1-protein inhibitor complex). The LMWH dosage averaged 9…

medicine.medical_specialtymedicine.diagnostic_testmedicine.drug_classbusiness.industryExtracorporeal circulationElastaseLow molecular weight heparinGeneral MedicineHeparinThrombin timeSurgeryIncreased riskBolus (medicine)AnesthesiamedicinebusinessPartial thromboplastin timemedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Drug-induced hepatitis: a rare complication of oral anticoagulants.

1994

Hepatotoxicity is a rare complication of coumarin anticoagulants. We present the case of a 56-year-old woman who developed a viral-hepatitis-like picture 8 months after mitral valve replacement and oral anticoagulation. Phenprocoumon-induced hepatitis was diagnosed after positive reexposure and improvement following withdrawal of the drug. There appeared to be cross-reactivity to warfarin since this drug led to a similar increase in alkaline phosphatase and gamma-glutamyl transferase after a few days of administration. Liver biopsy showed an acute viral-hepatitis-like picture. Anticoagulation was changed to a subcutaneous low molecular weight heparin and low-dose aspirin. Because of the wid…

medicine.medical_specialtymedicine.drug_classBiopsyLow molecular weight heparinAdministration OralGastroenterologyInternal medicinemedicineHumansHepatitisAspirinHepatologymedicine.diagnostic_testbusiness.industryIncidenceAnticoagulantWarfaringamma-GlutamyltransferaseMiddle Agedmedicine.diseaseAlkaline PhosphataseSurgeryLiverLiver biopsyPhenprocoumonFemaleWarfarinChemical and Drug Induced Liver InjurybusinessViral hepatitisComplicationmedicine.drugJournal of hepatology
researchProduct

Human antiphospholipid antibodies induce TNFα in monocytes via Toll-like receptor 8

2009

The antiphospholipid syndrome (APS) is characterized by recurrent arterial and/or venous thromboses, pregnancy loss and the presence of antiphospholipid antibodies (aPL). One of the discussed mechanisms of this thrombotic activity in APS patients is attributed to TNFalpha secretion in monocytes after aPL stimulation. To investigate this mechanism in detail, we employed a monoclonal aPL and IgG fractions of APS patients for stimulation of human peripheral monocytes. Stimulation with this monoclonal aPL resulted in an increased expression and secretion of TNFalpha, caused by specific upregulation of TLR8 mRNA and protein expression levels. To confirm the specificity of this finding we could d…

medicine.medical_specialtymedicine.drug_classBlotting WesternImmunologyEnzyme-Linked Immunosorbent AssayStimulationCell SeparationBiologyMonoclonal antibodyPeripheral blood mononuclear cellMonocytesProinflammatory cytokineDownregulation and upregulationimmune system diseasesAntiphospholipid syndromeInternal medicinemedicineHumansImmunology and AllergyReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaAntibodies MonoclonalHematologyAntiphospholipid SyndromeFlow Cytometrymedicine.diseaseEndocrinologyToll-Like Receptor 8MonoclonalImmunologyAntibodies AntiphospholipidElectrophoresis Polyacrylamide GelTumor necrosis factor alphaImmunobiology
researchProduct

Minimally invasive techniques in the treatment of saphenous varicose veins.

2008

Lower extremity venous insufficiency is common and increases with age. In addition to classical symptoms, it may result in skin changes and venous ulcers. Chronic venous insufficiency has a great impact on patients' health-related quality of life and is associated with considerable health care costs. Surgical ligation Of the junction with or without stripping has been the standard of care in the treatment of insufficient great and small saphenous veins. However, the recurrence rates are relatively high and surgery may be associated with serious adverse events and considerable down time; it is also cosmetically Suboptimal. To improve efficacy, patients' health-related quality of life and tre…

medicine.medical_specialtymedicine.drug_classChronic venous insufficiencyRadiofrequency ablationmedicine.medical_treatmentLow molecular weight heparinDermatologylaw.inventionVaricose VeinsQuality of lifelawVaricose veinsSclerotherapymedicineSclerotherapyHumansMinimally Invasive Surgical ProceduresSaphenous VeinAdverse effectbusiness.industryGreat saphenous veinmedicine.diseaseSurgeryCatheter AblationLaser Therapymedicine.symptombusinessJournal of the American Academy of Dermatology
researchProduct

OC-01 - Clinical history of cancer patients with isolated distal deep vein thrombosis: a multicenter cohort study

2016

Introduction Isolated distal deep vein thrombosis (IDDVT) accounts for one-fourth to one-half of all deep vein thrombosis (DVT) of the leg. Patients with IDDVT are frequently treated for a shorter period of time compared to patients with proximal DVT and/or pulmonary embolism (PE) due to a perceived lower risk of recurrence. About 10-20% of patients with venous thromboembolic events (VTEs) have concomitant cancer. Guidelines recommend long-term anticoagulant treatment in this group of patients due to their high risk of VTE recurrence. Unfortunately, information on the clinical history of IDDVT patients is limited and, to date, no study has evaluated the long-term risk of VTE recurrence in I…

medicine.medical_specialtymedicine.drug_classDeep veinPopulationLow molecular weight heparin030204 cardiovascular system & hematologyLower riskGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicinecancerVeineducationThrombosis history; distal deep vein thrombosis;cancerThrombosis historyeducation.field_of_studybusiness.industrydistal deep vein thrombosiHematologymedicine.diseaseThrombosisPulmonary embolismSurgeryVenous thrombosismedicine.anatomical_structure030220 oncology & carcinogenesisbusinessThrombosis Research
researchProduct

Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anti…

2012

Abstract Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist such as warfarin. However, this option is not without its limitations, as the anticoagulant effect of warfarin is associated with high inter- and intra-patient variability and patients must be regularly monitored to ensure that anticoagulation is within the narrow target therapeutic range. Several novel oral anticoagulant agents are in the advanced stages of development for VTE treatment, some of which are given after an initial period of heparin treatment, in line with current p…

medicine.medical_specialtymedicine.drug_classDeep veinReviewTherapeutic indexRecurrencemedicinecardiovascular diseasesIntensive care medicinebusiness.industryHeparinlcsh:RC633-647.5AnticoagulantBleedingWarfarinAnticoagulantsHeparinlcsh:Diseases of the blood and blood-forming organsHematologyVitamin K antagonistmedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structureVitamin K antagonistsbusinessmedicine.drugVenous thromboembolismThrombosis Journal
researchProduct

Prolonged anticoagulant treatment in patients with cancer: Where do we stand?

2017

medicine.medical_specialtymedicine.drug_classLow molecular weight heparin030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineTinzaparinRecurrenceNeoplasmsInternal medicineHumansMedicineCancer associated thrombosisIn patientbusiness.industryLow molecular weight heparinCancer associated thrombosiBleedingAnticoagulantsCancerHematologyTinzaparinmedicine.diseaseAnticoagulant therapy030220 oncology & carcinogenesisbusiness
researchProduct

Blood Coagulation and Thrombosis in Patients with Ovarian Malignancy

1997

SummaryOvarian cancer cells appear to be capable of both thrombin formation and induction of fibrin degradation which may be essential prerequisites for the development of deep vein thrombosis (DVT) as well as the spread of malignancy. To study further this coagulation – cancer interaction in 60 patients with untreated ovarian cancer of FIGO stage I-IV the incidence of DVT was recorded pre-operatively, postoperatively on day 1, 3, 5, 7, 10, before each of six cycles of Cisplati- num/Epirubicin/Cyclophosphamide chemotherapy, during follow-up and in the post-operative period of second look surgery. In addition, blood coagulation tests results were determined prospectively. Two patients were e…

medicine.medical_specialtymedicine.drug_classLow molecular weight heparinGastroenterologyPostoperative ComplicationsMedian follow-upThromboembolismInternal medicinemedicineHumansProspective Studiescardiovascular diseasesBlood CoagulationAgedBlood coagulation testOvarian NeoplasmsUnivariate analysisHeparinbusiness.industryAntithrombinAnticoagulantAnticoagulantsHematologyHeparinHeparin Low-Molecular-WeightMiddle AgedSurvival AnalysisSurgeryFemaleBlood Coagulation Testsbusinessmedicine.drugEpirubicinThrombosis and Haemostasis
researchProduct

Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice.

2010

The constitutive androstane receptor (CAR) is a nuclear receptor expressed in the liver and involved in xenobiotic metabolism. The aim of this study was to assess whether pharmacological CAR activation could affect neutral sterol and bile acid elimination under conditions of cholesterol overload.Wild type, Car-/-, ApoE-/-, and low-density lipoprotein receptor (Ldlr)-/- mice fed a western-type diet were treated with the CAR agonist TCPOBOP.CAR activation was associated with a decrease in faecal cholesterol output related to the repression of the Abcg5/g8 cholesterol transporters. In contrast, TCPOBOP treatment induced a marked increase (up to three fold, p0.01) in the elimination of faecal b…

medicine.medical_specialtymedicine.drug_classPyridinesLipoproteinsBiological Transport ActiveGene ExpressionReceptors Cytoplasmic and NuclearHyperlipidemiasBiologyCholesterol 7 alpha-hydroxylaseBile Acids and Saltschemistry.chemical_compoundFecesMiceApolipoproteins EInternal medicineConstitutive androstane receptormedicineAnimalsHomeostasisATP Binding Cassette Transporter Subfamily G Member 5Liver X receptorConstitutive Androstane ReceptorMice KnockoutHepatologyBile acidCholesterolReverse cholesterol transportATP Binding Cassette Transporter Subfamily G Member 8Cholesterol HDLAtherosclerosisSterolMice Inbred C57BLEndocrinologyCholesterolchemistryLiverReceptors LDLLDL receptorlipids (amino acids peptides and proteins)ATP-Binding Cassette TransportersJournal of hepatology
researchProduct